PERRIGO Co plc (PRGO) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Jun-27-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues:
Rx Pharmaceuticals					920.8	1,054.4		936.0
Other					3,810.9	3,891.8		3,291.1
Total revenues [+]	4,451.6	4,138.7	4,088.2	3,869.9	4,731.7	4,946.2	5,280.6	4,227.1
Products	4,451.6	4,138.7	4,088.2	3,869.9	4,731.7	4,946.2	5,280.6
Revenue growth [+]	7.6%	1.2%	5.6%	-18.2%	-4.3%	-6.3%		4.1%
Rx Pharmaceuticals					-12.7%			1.0%
Other								-21.7%
Cost of goods sold	2,996.2	2,722.5	2,593.3	2,436.2	2,900.2	2,966.7	3,228.8	2,582.9
Gross profit	1,455.4	1,416.2	1,494.9	1,433.7	1,831.5	1,979.5	2,051.8	1,644.2
Gross margin	32.7%	34.2%	36.6%	37.0%	38.7%	40.0%	38.9%	38.9%
Selling, general and administrative [+]	1,210.1	1,111.4	1,109.1	1,097.2	1,125.8	1,146.5	1,205.5	772.0
Sales and marketing	584.8	536.4	545.5	538.7	595.7	598.4	665.0	319.0
General and administrative	512.3	482.0	478.5	476.5	435.9	461.1	452.2	385.3
Other selling, general and administrative	113.0	93.0	85.1	82.0	94.2	87.0	88.3	67.7
Research and development	123.1	122.0	121.7	119.2	218.6	167.7	184.0	187.8
Other operating expenses	0.8	-417.6	-4.3	2.9	5.2	-41.4
EBITDA [+]	460.0	912.6	653.2	610.9	905.5	1,151.5	1,119.3	943.1
EBITDA growth	-49.6%	39.7%	6.9%	-32.5%	-21.4%	2.9%		-3.7%
EBITDA margin	10.3%	22.1%	16.0%	15.8%	19.1%	23.3%	21.2%	22.3%
Depreciation	86.2	102.2	172.6	176.9	90.0	95.2	100.2	84.2
EBITA	373.8	810.4	480.6	434.0	815.5	1,056.3	1,019.1	858.9
EBITA margin	8.4%	19.6%	11.8%	11.2%	17.2%	21.4%	19.3%	20.3%
Amortization of intangibles	252.4	210.0	212.2	219.6	333.6	349.6	356.8	174.5
EBIT [+]	121.4	600.4	268.4	214.4	481.9	706.7	662.3	684.4
EBIT growth	-79.8%	123.7%	25.2%	-55.5%	-31.8%	6.7%		10.4%
EBIT margin	2.7%	14.5%	6.6%	5.5%	10.2%	14.3%	12.5%	16.2%
Non-recurring items [+]	42.5	190.0	3.2	39.7	245.4	108.5	2,662.0	11.9
Asset impairment		173.1		13.8	224.4	47.5	2,631.0	6.8
Interest expense	156.0	125.0	127.7	117.5	128.0	168.1	216.6	146.0
Interest expense	156.0	125.0	127.7	117.5	128.0	168.1	216.6	146.0
Other income (expense), net [+]	-70.2	362.9	-169.9	80.1	341.7	10.5	-2,632.0	-266.2
Gain (loss) on debt retirement	-8.9		-20.0	-0.2	-0.5	-135.2	-1.1	-10.5
Other	-53.1	-26.7	-16.3	68.9	-6.1	10.1	-22.7	-334.2
Pre-tax income	-147.3	648.3	-32.4	137.3	450.2	440.6	-4,848.3	260.3
Income taxes	-8.2	389.6	-38.3	-10.7	159.6	160.5	-835.5	124.2
Tax rate	5.6%	60.1%	118.2%		35.5%	36.4%	17.2%	47.7%
Net income	-139.1	258.7	5.9	148.0	290.6	280.1	-4,012.8	136.1
Net margin	-3.1%	6.3%	0.1%	3.8%	6.1%	5.7%	-76.0%	3.2%

Basic EPS [+]	($1.03)	$1.94	$0.04	$1.09	$2.11	$1.97	($28.00)	$0.98
Growth	-153.4%	4366.8%	-96.0%	-48.4%	7.1%	-107.0%		-154.8%
Diluted EPS [+]	($1.03)	$1.94	$0.04	$1.08	$2.10	$1.96	($28.00)	$0.97
Growth	-153.4%	4402.9%	-96.0%	-48.4%	7.0%	-107.0%		-154.8%

Dividends per share [+]	$1.04	$0.96	$0.90	$0.82	$0.76	$0.64	$0.58	$0.46
Growth	8.3%	6.7%	9.8%	7.9%	18.8%	10.3%		17.9%

Shares outstanding (basic) [+]	134.5	133.6	136.1	136.0	137.8	142.3	143.3	139.3
Growth	0.7%	-1.8%	0.1%	-1.3%	-3.2%	-0.7%		21.0%
Shares outstanding (diluted) [+]	134.5	133.6	137.2	136.5	138.3	142.6	143.3	139.8
Growth	0.7%	-2.6%	0.5%	-1.3%	-3.0%	-0.5%		20.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.